1. Scrip

Recent Financings of Private Companies (03/2007)

Each month, Start-Up presents a comprehensive review of young, private life science companies that have recieved venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.

Jan.—DiaDexus (developed a blood test to predict cardiovascular disease and is working on one for breast cancer) has raised $40mm through its Series E venture round. Returning backers Baker Brothers and Scale Venture Partners co-led the financing and were joined by fellow shareholders GlaxoSmithKline, Rho Ventures, Bain Capital's Brookside Fund, and Mosaix Ventures as well as new investor Burrill & Co.

Feb.—Biofusion PLC has spun off a new company, Absynth Biologics Ltd. , which will develop vaccines and antibodies against Staphylococcus...

More from Archive

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.